Unlocking the potential of a new class of drugs-Angiotensin II Type 2 Receptor Agonists (ATRAGs)

Webinar - Final phase 2a AIR trial results with buloxibutid in IPF

View replay

Financial reports

Latest press releases

2024-09-30 Vicore Announces Investment from Sanofi

2024-09-18 Vicore Publishes Prospectus Relating to the Rights Issue

Upcoming events

Who we are

Vicore is an innovative clinical-stage pharmaceutical company dedicated to creating life- changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology.

We have a strong history of collaboration with the scientific community, which has led to a wealth of preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology. Embedded in our approach is the determination to find holistic solutions for patients and their families.

Mechanism of Action

In IPF, the novel and multimodal mechanism of action of buloxibutid (C21) targets the underlying fibrosis by stimulating the protective arm of the renin-angiotensin system (RAS). Consequently, there is an upstream effect in terms of promoting alveolar repair and maintenance of alveolar integrity thereby reducing fibrosis formation, stabilizing disease, and increasing lung capacity.

Read more about the broad therapeutic potential of AT2 receptor activation.

What we do

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF).

Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF.

Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee™ has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact.

Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. >> View Pipeline

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market.